Four of the eight children
experienced cytokine release syndrome.
All patients who received the CTL019 «hunter» cells
experienced a cytokine release syndrome (CRS) within a few days after receiving their infusions — a key indicator that the engineered cells have begun proliferating and killing tumor cells in the body.
Not exact matches
All 10 patients who received the CTL119 cells
experienced mild
cytokine release syndrome (CRS), a known potentially lethal type of toxicity, within a few days after receiving their infusions; however, none required treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory
cytokine IL - 6.
What's more, none of the patients
experienced macrophage activate syndrome or
cytokine release syndrome, an infusion reaction observed in other gene therapy trials characterized by fever, nausea, chills, hypotension or a rash.
After receiving the engineered cells, she
experienced no fevers or other signs of
cytokine release syndrome (CRS), a condition that has been observed in other patients undergoing CTL019.